GlobeNewswire Inc | Jul 28, 2021 04:05PM EDT

July 28, 2021

SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 41st Annual Growth Conference, being held virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET (12:00 p.m. PT).

A live webcast of the presentation may be accessed under the Investors & Media section of Olemas website (www.olema.com) and will be archived for 14 days.

About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers. Olemas lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

ContactEva StroynowskiVice President, Communications and Investor Relationseva@olema.com